CABA270115C00003000
CABA Jan 15 2027 3.00 Call
optionOPRA
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 16, 2026 | 11d | $0.05 | -37.50% | 1 | 1,238 |
| Nov 20, 2026 | 46d | $0.05 | +0.00% | 20 | 526 |
| Jan 15, 2027 | 102d | $0.12 | -33.33% | 2 | 2,094 |
| Feb 19, 2027 | 137d | $0.10 | -83.33% | 4 | 163 |
| May 21, 2027 | 228d | — | — | 0 | 0 |
| Jan 21, 2028 | 473d | $0.73 | -14.12% | 8 | 829 |
| Jan 19, 2029 | 837d | $1.30 | -13.33% | 4 | 67 |
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| .5 C | $2.14 | -0.47% | 44 | 83 | ITM |
| 1 C | $0.90 | -46.75% | 44 | 53 | ITM |
| 1.5 C | $1.00 | -9.09% | 1 | 238 | ITM |
| 2 C | $0.41 | -25.45% | 273 | 225 | OTM |
| 2.5 C | $0.25 | -39.02% | 1 | 788 | OTM |
| 3 C | $0.12 | -33.33% | 2 | 2,094 | OTM |
| 3.5 C | $0.15 | +50.00% | 1 | 786 | OTM |
| 4 C | $0.10 | -81.13% | 7 | 195 | OTM |
| 4.5 C | $0.95 | +72.73% | 10 | 69 | OTM |
| 5 C | $0.05 | -54.55% | 21 | 2,447 | OTM |
| 5.5 C | $0.35 | -22.22% | 3 | 189 | OTM |
| 7.5 C | $0.15 | -61.54% | 11 | 32 | OTM |
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un